Compare · BKHA vs GILD
BKHA vs GILD
Side-by-side comparison of Black Hawk Acquisition Corporation (BKHA) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BKHA and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD carries a market cap of $161.88B.
- Over the past year, BKHA is up 10.4% and GILD is up 22.6% - GILD leads by 12.2 points.
- GILD has been more active in the news (8 items in the past 4 weeks vs 2 for BKHA).
- GILD has more recent analyst coverage (25 ratings vs 0 for BKHA).
- Company
- Black Hawk Acquisition Corporation
- Gilead Sciences Inc.
- Price
- $11.65+0.52%
- $130.38-2.48%
- Market cap
- -
- $161.88B
- 1M return
- +0.52%
- -5.67%
- 1Y return
- +10.43%
- +22.62%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 1992
- News (4w)
- 2
- 8
- Recent ratings
- 0
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest BKHA
- SEC Form 10-Q filed by Black Hawk Acquisition Corporation
- SEC Form NT 10-Q filed by Black Hawk Acquisition Corporation
- Black Hawk Acquisition Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
- Black Hawk Acquisition Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-K filed by Black Hawk Acquisition Corporation
- SEC Form NT 10-K filed by Black Hawk Acquisition Corporation
- Black Hawk Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Black Hawk Acquisition Corporation filed SEC Form 8-K: Leadership Update
- Amendment: SEC Form S-4/A filed by Black Hawk Acquisition Corporation
Latest GILD
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
- SEC Form 4 filed by Dickinson Andrew D
- SEC Form 4 filed by Mercier Johanna
- PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
- Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
- EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
- Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
- Gilead Extends Tender Offer to Acquire Arcellx
- SEC Form 4 filed by O'Day Daniel Patrick